Impact of the metabolic syndrome on the predictive values of new risk markers in the general population

Journal of Human Hypertension

Volumn 22, Issue 9, 2008, Pages 634-640

  Olsen, M H ^a   Hansen, T W ^a   Christensen, M K ^a   Gustafsson, F ^b   Rasmussen, S ^a   Wachtell, K ^b   Ibsen, H ^c   Torp Pedersen, C ^d   Hildebrandt, P R ^e  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

^c HOLBÆK HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CREATININE URINE LEVEL; DISEASE ASSOCIATION; FEMALE; HEART DEATH; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; SEX RATIO; SMOKING;

ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CREATININE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 50449087020     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.40     Document Type: Article

References (31)

1. Olsen MH, Christensen MK, Hansen TW, Gustafsson F, Rasmussen S, Wachtell K et al. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. J Hypertens 2006; 24: 655-661.
2. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005; 46: 660-666.
3. Ingelsson E, Sullivan LM, Murabito JM, Fox CS, Benjamin EJ, Polak JF et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes 2007; 56: 1718-1726.
4. Pedrinelli R, Dell'Omo G, Penno G, Di BV, Giorgi D, Pellegrini G et al. Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. J Hypertens 2003; 21: 1163-1169.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
6. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
7. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.
8. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arteriascler Thromb Vasc Biol 1999; 19: 1992-1997.
9. de SG, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: The LIFE study. J Hum Hypertens 2007; 21: 625-632.
10. Aguilar D, Fisher MR, O'Connor CM, Dunne MW, Muhlestein JB, Yao L et al. Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease. Am Heart J 2006; 152 298-304.
11. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40 1286-1292.
12. Hak AE, Pols HA, Stehouwer CD, Meijer J, Kiliaan AJ, Hofman A et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: The Rotterdam Study. J Clin Endocrinol Metab 2001; 86: 4398-4405.
13. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-1137.
14. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-1710.
15. Pannacciulli N, Cantatore FP, Minerma. A, Bellacicco M, Giorgino R, De Pergola G. Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women. J Intern Med 2001; 250: 502-507.
16. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: A LIFE study. J Hypertens 2004; 22: 1597-1604.
17. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007; 28: 1374-1381.
18. Drivsholm T, Ibsen H, Schroll M, Davidsen M, Borch-Johnsen K. Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes. Diabet Med 2001; 18: 126-132.
19. Guerrero-Romero F, Rodriguez-Moran M. Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. Diabetes Care 2005; 28: 2588-2589.
20. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: A comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56: 124-130.
21. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338: 107-115.
22. Rowe DJ, Dawnay A, Watts GF. Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 1990; 27: 297-312.
23. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K et al. Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex. J Hypertens 2008; 26: 26-34.
24. Tamura K, Takahashi N, Nakatani Y, Onishi S, Iwasaka T. Prognostic impact of plasma brain natriuretic peptide for cardiac events in elderly patients with congestive heart failure. Gerontology 2001; 47 46-51.
25. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-1021.
26. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-663.
27. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165.
28. McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP. Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991; 84: 1273-1278.
29. Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 1710-1716.
30. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595-600.
31. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955-1959.